tbuckley/cabot-search huggingface dataset:
HG-51DELTA-24-RDG IN COMBINATION WITH RADIOTHERAPY FOR DIPG: OPENING NEW THERAPEUTIC AVENUES
Authors: Naiara Martinez-Velez, Miguel Marigil, Pablo Dominguez, Javier Aristu, Juan Fueyo, Cande Gomez-Manzano, Marie Piere Junier, Herve Chneiweiss, Elias A. El-Habr, Ricardo Diaz-Valle, Sonia Tejada, Marta M. Alonso
Journal: Neuro-Oncology (2016)
PTPS-11ATYPICAL TERATOID/RHABDOID TUMOUR IS AN EPIGENETICALLY HETEROGENEOUS DISEASE CHARACTERIZED BY SUBGROUP SPECIFIC SUPER-ENHANCERS
Authors: Pascal D. Johann, Serap Erkek, Marc Zapatka, Kornelius Kerl, Ivo Buchhalter, Volker Hovestadt, Andrey Korshunov, Rhyzova Marina, David T.W. Jones, Paul A. Northcott, Michael Frühwald, Amar Gajjar, Martin Hasselblatt, Stefan M. Pfister, Marcel Kool
Journal: Neuro-Oncology (2015)

Atypical teratoid/rhabdoid tumor (ATRT) is one of the most common brain tumors in infants or young children. Although the prognosis of ATRT patients is poor, some patients respond very well to current treatments, suggesting inter-tumor molecular heterogeneity. To investigate this, we have analyzed a large cohort of 152 ATRTs genetically and epigenetically. Three distinct molecular subgroups of ATRTs, associated with differences in patient's age, tumor location and type of SMARCB1 mutations, were identified using DNA-methylation and gene expression analyses which we have termed ATRT-TYR, ATRT-SHH, ATRT-MYC after genes and pathways that were highly overexpressed in the subgroups. Whole genome DNA- or RNA-sequencing found no other additional recurrent mutations explaining the differences between subgroups. However, whole genome bisulfite-sequencing and H3K27ac ChipSequencing of primary tumors revealed clear epigenetic differences and showed that ATRT genomes in two of the three subgroups were overall hypermethylated: Large partially methylated domains (PMDs) were only frequently present in subgroups ATRT-SHH and ATRT-MYC and genes encompassed by these regulatory elements were often downregulated in these subgroups. By statistical testing, we derived subgroup specific enhancers from the H3K27ac ChipSequencing data that characterize the three subgroups and developed a model for enhancer-gene regulation. Among the subgroup specifically regulated genes were key components of the SHH pathway for ATRT-SHH (such as GLI2) and members of the melanogenesis pathway (such as the transcription factor MITF) for subgroup ATRT-TYR. Having identified MITF as a central regulatory hub in this subgroup, we performed ChipSequencing for this molecule and found that genes previously implicated in ATRT biology (such as BMP4 and CCND1) were important targets of this transcription factor. In summary, by examining various levels of data, we could find clear epigenetic evidence for three ATRT subgroups and identified regulatory molecules for the subgroups that may be used as a target in subsequent clinical studies.
PCM-22A NEW APPROACH OF PRECLINICAL TESTING OF CHEMOTHERAPIES - AN EXAMPLE OF BRAIN TUMOUR THERAPY
Authors: Birgit Nimmervoll, Yogesh Patel, Brandon Bianski, Michael DeCuypere, Anang Shelat, Clinton Stewart, Tom Merchant, R. Kip Guy, Richard Gilbertson
Journal: Neuro-Oncology (2016)
Interferons as biochemical modulators.
Authors: E C Borden, S Wadler
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.10.2627 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8874320 Interferons as biochemical modulators. E C BordenxE C BordenSearch for articles by this author , S WadlerxS WadlerSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.10.2627 First Page PDF © 1996 by American Society of Clinical Oncology
Phosphate transport in brush border membranes from uremic rats. Response to phosphonoformic acid.
Authors: M Loghman-Adham, M Szczepanska-Konkel, T P Dousa
Journal: Journal of the American Society of Nephrology (1992)

Phosphate retention in chronic renal failure may result in the development of secondary hyperparathyroidism and renal osteodystrophy. Thus, the addition of a specific phosphaturic agent may be beneficial in the treatment of chronic renal failure. Phosphonoformic acid (PFA), a specific and competitive inhibitor of Na(+)-Pi cotransport in renal and intestinal brush border membrane vesicles (BBMV), can induce phosphaturia in thyroparathyroidectomized (TPTX) rats. The aim of this study was to determine if PFA retains its inhibitory activity in uremic intestine and kidney. The effect of PFA, and its derivative phosphonoacetic acid (PAA), added in vitro, on Pi transport in BBMV prepared from the intestine and the remnant kidney of 5/6 nephrectomized (NX) rats was studied. In intestinal BBMV, the time course of Pi transport was not significantly different between NX and sham-operated (SH) control rats. Compared with SH, Na(+)-dependent Pi transport was reduced in BBMV from remnant kidney of NX, with no difference in Na(+)-independent or equilibrium uptakes. The reduced transport was specific for Pi with no change in Na+ gradient-dependent L-proline uptake, suggesting a normal Na+ conductance in uremic BBM. PFA and PAA produced a marked inhibition of Na(+)-Pi cotransport in intestinal and renal BBMV from NX and SH with similar relative inhibitory potency in uremic and control BBMV. It was concluded that the relative inhibitory potency of PFA or PAA on intestinal and renal Na(+)-Pi cotransport is preserved in uremia.
Statement by the Albert and Mary Lasker Foundation
Authors: M Lasker
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic Sclerotherapy versus Port Acaval Shunt in Patients with Severe Cirrhosis and Acute Variceal Hemorrhage
Authors: John P. Cello, James H. Grendell, Richard A. Crass, Thomas E. Weber, Donald D. Trunkey
Journal: New England Journal of Medicine (1987)

In a continuation of a trial for which preliminary results were reported in the Journal two years ago, a total of 64 patients with Child Class C cirrhosis and variceal hemorrhage requiring six or more units of blood were randomly assigned to receive either a portacaval shunt (32 patients) or endoscopic sclerotherapy (32 patients). The duration of initial hospitalization and the total amount of blood transfused during hospitalization were significantly less in the patients receiving sclerotherapy (P<0.001). There was no difference in short-term survival (50 percent of the sclerotherapy group were discharged alive, as compared with 44 percent of the shunt-surgery group). Both groups were followed for a mean of 530 days after randomization. Rebleeding from varices, the duration of rehospitalization for hemorrhage, and transfusions received after discharge were all significantly greater in the sclerotherapy group (P<0.001). Forty percent of the sclerotherapy-treated patients discharged alive (7 of 16 patients) ultimately required surgical treatment for bleeding varices, despite a mean of 6.1 treatment sessions. Health care costs and long-term survival did not differ significantly between the groups (P>0.05). We conclude that although endoscopic sclerotherapy is as good as surgical shunting for the acute management of variceal hemorrhage in poor-risk patients with massive bleeding, sclerotherapy-treated patients in whom varices are not obliterated and bleeding continues should be considered for elective shunt surgery. (N Engl J Med 1987; 316:11–5.)
Prevention of congenital rubella and congenital varicella in Europe
Authors: R M Martin
Journal: Eurosurveillance (2009)

Preview this article: Prevention of congenital rubella and congenital varicella in Europe, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/14/14/art19167-en-1.gif
HG-22TREATMENT OF INTRA-BRAIN STEM XENOGRAFT MOUSE MODELS OF DIPG WITH COMBINED RADIATION AND ONCOLYTIC VIRAL THERAPY
Authors: Yuchen Du, Huiyuan Zhang, Lin Qi, Holly Lindsay, Mari Kogiso, Sibo Zhao, Frank K. Braun, Xiao-Nan Li
Journal: Neuro-Oncology (2016)
Dose-intensive metastatic breast cancer chemotherapy.
Authors: M H Cohen
Journal: Journal of Clinical Oncology (1996)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1996.14.2.685 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8636794 Dose-intensive metastatic breast cancer chemotherapy. M H CohenxM H CohenSearch for articles by this author https://doi.org/10.1200/JCO.1996.14.2.685 PDF "Dose-intensive metastatic breast cancer chemotherapy.." Journal of Clinical Oncology, 14(2), pp. 685–686© 1996 by American Society of Clinical Oncology
Case 7-1984
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, H. R. Jones, J. J. Halperin
Journal: New England Journal of Medicine (1984)

Presentation of CaseA 34-year-old man was admitted to the hospital because of a progressive Central-nervous-system disorder.The patient was born of an uneventful pregnancy and delivery and developed normally in his early years. At the age of 14 years he was a "B" student and participated actively in sports. At about this time his parents began to notice that he walked with a shuffling gait, with his head held erect and tilted backward. If seated on a bench without back support he slowly leaned backward until he fell. He gave up playing the trumpet because of inability to manipulate . . .
Clinical Validation of Chemotherapy Response Biomarker<i>ERCC2</i>in Muscle-Invasive Urothelial Bladder Carcinoma
Authors: David Liu, Elizabeth R. Plimack, Jean Hoffman-Censits, Levi A. Garraway, Joaquim Bellmunt, Eliezer Van Allen, Jonathan E. Rosenberg
Journal: JAMA Oncology (2016)

10 PD events were colon and prostate cancer, which were also unrelated to earlier PD (Table 2).Discussion | Both cancer and PD occur primarily at advanced ages and can be debilitating.Consequently, medical surveillance for cancer could be influenced by a prior PD diagnosis, which may bias the observed PD-cancer associations.Moreover, patterns of medical surveillance may differ by health care system (eg, US Medicare and Taiwan National Health Insurance Research Database).It is therefore important that in evaluating PD-cancer associations investigators adjust for medical surveillance and include negative controls.Although we cannot rule out small risks attributable to sample size, we did not find a positive association between PD and subsequent cancer in Asian Americans in SEER-Medicare data.Although according to SEER-Medicare data Asian Americans are ethnically more diverse than the Taiwanese population, our null findings do not support the hypothesis that ethnicity is a major contributor to the elevated risk in the study by Lin et al. 4 The elevated risks observed in the study by Lin et al 4 could reflect various factors, including possibly more cancer surveillance after PD.
Comparison of the Number of Breast-Cancer Deaths Observed in Relatives of Breast-Cancer Patients, and the Number Expected on the Basis of Mortality Rates2
Authors: Madge T. Macklin
Journal: JNCI Journal of the National Cancer Institute (1959)

Journal Article Comparison of the Number of Breast-Cancer Deaths Observed in Relatives of Breast-Cancer Patients, and the Number Expected on the Basis of Mortality Rates Get access Madge T. Macklin Madge T. Macklin Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 22, Issue 5, May 1959, Pages 927–951, https://doi.org/10.1093/jnci/22.5.927 Published: 01 May 1959 Article history Received: 30 October 1958 Published: 01 May 1959
GC-13SALVAGE HIGH-DOSE CHEMOTHERAPY FOR PATIENTS WITH RECURRENT CENTRAL NERVOUS SYSTEM GERM-CELL TUMOURS
Authors: Takaaki Yanagisawa, Kohei Fukuoka, Tomonari Suzuki, Masanori Yamaoka, Wataru Yamaoka, Kentaro Yokoi, Masaharu Akiyama, Ai Masumoto, Yuichiro Nonaka, Junichi Adachi, Kazuhiko Mishima, Ryo Nisikawa
Journal: Neuro-Oncology (2016)
MB-33CLINICAL CHARACTERISTICS OF PATIENTS WITH GERMLINE SUFU MUTATIONS
Authors: Léa Guerrini Rousseau, Marine Guillaud Bataille, Franck Bourdeaut, Stéphanie Puget, Christelle Dufour, Jacques Grill, Brigitte Bressac, Eric Sariban, Catherine Vilain, Bertrand Isidor, Ludovic Mansuy, Ingrid Winship, Olivier Delattre, Dominique Valteau Couanet, Laurence Brugières
Journal: Neuro-Oncology (2016)
PERIODIC HEALTH EXAMINATIONS
Authors: F H SHILLITO
Journal: Annals of Internal Medicine (1953)

Article1 July 1953PERIODIC HEALTH EXAMINATIONSFREDERICK H. SHILLITO, M.D., F.A.C.P.FREDERICK H. SHILLITO, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-39-1-7 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONInterest in periodic health examination programs is increasing. Larger and larger industrial groups are undergoing regular periodic health surveys. Individuals, stimulated by insurance companies and other enlightened agencies, are seeking out this phase of preventive medicine. Veterans of our military service, particularly from such groups as flying personnel of the Air Force, have been indoctrinated in the idea of frequent surveys of the physical status of the individual.Irrespective of the ways and means of motivation, the individual turns to the medical profession for the accomplishment of the examination. The doctor is the corner-stone of the entire program. He...Bibliography1. Johnson HJ: Health of the executive, Proc. Life Ext. Exam. 2: 128, 1940. Google Scholar2. Kuh C: Periodic health examination vs. early sickness consultations, Permanente Found. M. Bull. 3: 12, 1945. Google Scholar3. Johnson HJ: Personal communication. Google Scholar4. Shillito FH: Appraisal of industrial health examinations, New York State J. Med. 50: 2163-2166 (Sept. 15) 1950. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Presented at the Thirty-fourth Annual Session of the American College of Physicians, Atlantic City, New Jersey, April 14, 1953. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 July 1953Volume 39, Issue 1Page: 7-14KeywordsArmed forcesHealth surveysMotivationPreventive medicine ePublished: 1 December 2008 Issue Published: 1 July 1953 PDF downloadLoading ...
Accelerating tuberculosis elimination in low-incidence settings: the role of genomics
Authors: Giovanni Sotgiu, Daniela M. Cirillo, Paolo Miotto, Rosella Centis, Giovanni Battista Migliori
Journal: European Respiratory Journal (2015)

We read with interest the correspondence by J.L. Guthrie and J.L. Gardy, which discussed the role of whole genome sequencing (WGS) in tuberculosis (TB) elimination based on the recently published World Health Organization (WHO) article [1]. The WHO document [1] focused on the priority interventions that should be applied by countries aiming to achieve TB pre-elimination ( i.e. TB incidence <10 cases per million inhabitants) and elimination ( i.e. TB incidence <1 case per million inhabitants) [1, 2]. The TB elimination strategy is expected to be initially adopted by low-TB incidence countries where the circulation of Mycobacterium tuberculosis strains is lower when compared to that observed in middle- and high-TB incidence countries. Whole genome sequencing may represent an important clinical and public health tool for tuberculosis elimination <http://ow.ly/TkGIt>
LG-19IMMUNOHISTOCHEMISTRY IS HIGHLY SENSITIVE AND SPECIFIC FOR THE DETECTION OF BRAF V600E STATUS IN PEDIATRIC LOW-GRADE GLIOMA
Authors: Matthew Mistry, Scott Ryall, Alvaro Lassaletta, Anthony Arnoldo, Ana Guerreiro Stucklin, Eric Bouffet, Uri Tabori, Cynthia Hawkins
Journal: Neuro-Oncology (2016)
NU-13EDUCATING PEDIATRIC HEMATO-ONCOLOGY STAFF MEMBERS IN COPING WITH DIFFERENT ASPECTS OF PARENTAL BEREAVEMENT, WITH AN EMPHASIS ON DEATH CAUSED BY BRAIN TUMORS
Authors: Ilana Ben-Zvi, Aviva Yamin, Inna Zetserov, Michal Schwartz, Ronit Elhasid, Rina Dvir
Journal: Neuro-Oncology (2016)
Geriatric psychiatry training: a brief clinical rotation
Authors: G D Cohen, J J O'Brien, J V Gillilan, T L Walsh, R Anthony
Journal: American Journal of Psychiatry (1980)

Burgeoning interest in geriatric psychiatry has created a challenge of optimally fitting geriatric content into already crowded psychiatric residency curricula. The authors review general considerations in geriatric psychiatry training and describe a brief clinical rotation for working with the elderly. The brief rotation is not presented as the ideal way of imparting geriatric psychiatry skills, but as an effective use of limited time to improve one's approach to the older patient. The clinical rotation enables the resident to learn more about psychiatric issues in later life, as well as to acquire a better perspective on other parts of the life cycle and on other aspects of psychiatry.
Two Uncommon Lymphomas
Authors: Ch. Jung, M. Gross, U. Kronawitter, S. Danhauser-Riedl, F.-D. Goebel, D. Schlondorff
Journal: Journal of Clinical Oncology (1999)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1999.17.2.726 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10080619 Two Uncommon Lymphomas Ch. JungxCh. JungSearch for articles by this author , M. GrossxM. GrossSearch for articles by this author , U. KronawitterxU. KronawitterSearch for articles by this author , S. Danhauser-RiedlxS. Danhauser-RiedlSearch for articles by this author , F.-D. GoebelxF.-D. GoebelSearch for articles by this author , D. SchlondorffxD. SchlondorffSearch for articles by this author Show More Ludwig-Maximilians-University, Munich, Germany https://doi.org/10.1200/JCO.1999.17.2.726 Full Text PDF Figures and Tables "Two Uncommon Lymphomas." Journal of Clinical Oncology, 17(2), p. 726© 1999 by American Society of Clinical Oncology
Routine vs. on-demand analgesia in colonoscopy: a randomized clinical trial
Authors: Øyvind Holme, Thomas de Lange, Asbjørn Stallemo, Håvard Wiig, Audun Hasund, Katrine Dvergsnes, Kjetil Garborg, Carl Ystrøm, Magnus Løberg, Geir Hoff, Michael Bretthauer, Mette Kalager
Journal: Endoscopy (2016)

<b>Background and study aims: </b>Colonoscopy is frequently performed with opioid analgesia, but the impact of drug delivery timing has not been studied in detail. Low-dose opioids administered before the procedure may provide better pain control than on-demand administration when the patient experiences pain. <b>Patients and methods:</b> A total of 119 outpatients were randomized to receive 50 μg of fentanyl either before colonoscopy (routine group) or on demand if needed during the colonoscopy (on-demand group). Additional fentanyl or midazolam was allowed in both groups if required. The primary outcome was pain measured on both a 100-mm visual analog scale (VAS; 0 = no pain, 100 = worst possible pain) and a four-point Likert scale (no, slight, moderate, or severe pain) immediately after the procedure. <b>Results:</b> A total of 61 patients in the routine group and 58 patients in the on-demand group were included in the study. Mean VAS pain scores were 27.4 mm in the routine group and 30.5 mm in the on-demand group (mean difference – 3.2 mm; 95 % confidence interval – 11.9 to 5.5; <i>P</i> = 0.5). On the Likert scale, moderate or severe pain was experienced by 25.0 % and 31.5 % of patients in the routine and on-demand groups, respectively (p = 0.5). Cecal intubation rate and time to reach the cecum were similar between the groups. More patients in the on-demand group (81.0 %) than in the routine group (62.3 %) were able to leave the clinic without the need for recovery time (<i>P</i> = 0.03). <b>Conclusion:</b> Routine administration of fentanyl did not provide better analgesia during colonoscopy than on-demand fentanyl, and more patients needed time for recovery. Trial registration: ClinicalTrials.gov (NCT01786434).
Electroconvulsive Therapy
Authors: S Servais, M Ansseau, G Mikolajczak, M Desseilles
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GC-19LONG-TERM EXPERIENCE WITH WHOLE VENTRICLE IRRADIATION (WVI) FOR CNS GERMINOMA (CNS-CGT)
Authors: Veronica Biassoni, Elisabetta Schiavello, Lorenza Gandola, Emilia Pecori, Barbara Diletto, Maura Massimino
Journal: Neuro-Oncology (2016)
Drug companies settle claim of misleading doctors on cancer survival data
Authors: Owen Dyer
Journal: BMJ (2016)

Roche’s Genentech and OSI Pharmaceuticals will pay $67 million (£47m; €60m) to settle claims that they misled doctors by inflating cancer survival data with their non-small cell lung cancer drug erlotinib (Tarceva). The case is the first time the US government has recovered money through the False Claims Act based on a drug manufacturer’s misleading statements about its drug’s survival data.

The False Claims Act is the US government’s instrument of choice for recovering money when it believes that companies have defrauded the public purse. Medical fraud accounted for more than half of the $3.5bn recovered last year. Typically this involved accusations of kickbacks …